Beyond their biological significance, several of these enriched pathways—such as estrogen signaling, PI3K-Akt signaling, Wnt signaling, and endocrine resistance—are therapeutically actionable and have been linked to treatment resistance in prostate cancer. This evidence concerns the gene AKT1 and prostate cancer.